Marcadores inflamatorios como factor pronóstico en el cáncer de próstata resistente a la castración metastásico

Donate-Moreno, María J.; Lorenzo-Sánchez, Marta Victoria; Migallón, I. Díaz de Mera-Sánchez; Herraiz-Raya, L.; Esper-Rueda, J.A.; Legido-Gómez, Óscar; Rico-Marco, Saúl; Salinas-Sánchez, Antonio S.

doi:10.1016/j.acuro.2020.08.001

Cited by 6 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Este conocimiento ha llevado a la realización de diversos estudios que han relacionado tanto el NLR como el PLR con el pronóstico en los diferentes tipos de cáncer como el de próstata, renal, gástrico, etc. (6,7,8,14,15,16,17,18,19,20,21,22,23) Para que se dé el proceso inflamatorio es necesario la participación de distintas células sanguíneas (neutrófilos, plaquetas, linfocitos, etc. ), siendo los neutrófilos, un subgrupo de leucocitos involucrados principalmente en este proceso.…”

Section: Resultados Y Discusiónunclassified

“…(17) Estudios previos informaron que una alta expresión de varios subtipos de linfocitos infiltrantes de tumores (TIL), como CD8+ o CD3+, se asocia con un mejor pronóstico en el cáncer gástrico. (28,29) Los resultados obtenidos de estos marcadores inflamatorios revisados en varios trabajos de investigación (14,15,16,17,18,19,20,21,22) se correlacionan con estudios realizados de otros tumores como el cáncer renal (6) y el de próstata (8) . Aquí se muestran que valores elevados de los cocientes PLR y NLR generan un peor pronóstico en pacientes con cáncer.…”

Section: Resultados Y Discusiónunclassified

“…Principalmente varios estudios han investigado la relación plaquetas/ linfocitos (PLR) y la relación neutrófilos / linfocitos (NLR) (6,7,8,9) en varios tipos de cáncer como en el cáncer de próstata, renal, gástrico, etc. El PLR es un cociente entre el número de plaquetas y el de linfocitos.…”

unclassified

See 2 more Smart Citations

Prognostic efficacy of platelet/lymphocyte ratio and neutrophil/lymphocyte ratio in patients with gastric cancer

Freire¹,

Freire²

2023

Salud, Ciencia y Tecnología

View full text Add to dashboard Cite

Cancer is the main cause of death before age 70. Gastric cancer (GC) is responsible for 1 in 13 deaths worldwide and is predominant in men. Inflammation is closely related to cancer, as it activates different blood cells such as neutrophils, lymphocytes, platelets, etc. A bibliographic review was carried out to collect and analyze studies concerning the prognostic efficacy of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patients with gastric cancer. Upon analysis, several studies indicated that elevated values of both NLR and PLR show poor prognosis. However, we suggest that more research is needed to obtain cutoff values according to GC staging, in order to be a helpful tool in GC diagnosis and prognosis.

show abstract

Section: Resultados Y Discusiónunclassified

See 1 more Smart Citation

Prognostic efficacy of platelet/lymphocyte ratio and neutrophil/lymphocyte ratio in patients with gastric cancer

Freire¹,

Freire²

2023

Salud, Ciencia y Tecnología

View full text Add to dashboard Cite

show abstract

Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort

Neuberger

Goly

Skladny

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Advances in therapy of metastatic castration-refractory prostate cancer (mCRPC) resulted in more therapeutic options and led to a higher need of predictive/prognostic biomarkers. Systemic inflammatory biomarkers could provide the basis for personalized treatment selection. This study aimed to assess the modified Glasgow Prognostic Score (mGPS), the neutrophile-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR) and the systemic immune-inflammation index (SII) in men with mCRPC under docetaxel. Methods Patients with mCRPC and taxane chemotherapy at a tertiary care centre between 2010 and 2019 were screened retrospectively. The biomarkers mGPS, NLR, PLR and SII were assessed and analyzed for biochemical/radiologic response and survival. Results We included 118 patients. Of these, 73 (61.9%) had received docetaxel as first-line, 31 (26.2%) as second-line and 14 (11.9%) as third-line treatment. For biochemical response, mGPS (odds ratio (OR) 0.54, p = 0.04) and PLR (OR 0.63, p = 0.04) were independent predictors in multivariable analysis. SII was significant in first-line cohort only (OR 0.29, p = 0.02). No inflammatory marker was predictive for radiologic response. In multivariable analysis, mGPS and NLR (hazard ratio (HR) 1.71 and 1.12, both p < 0.01) showed significant association with OS in total cohort and mGPS in the first-line cohort (HR 2.23, p < 0.01). Haemoglobin (Hb) and alkaline phosphatase (AP) showed several significant associations regarding 1 year, 3 year, OS and biochemical/radiologic response. Conclusions Pre-treatment mGPS seems a promising prognostic biomarker. A combination of mGPS, NLR and further routine markers (e.g., Hb and AP) could yield optimized stratification for treatment selection. Further prospective and multicentric assessment is needed.

show abstract

Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors

Urakçı,

Ebinç,

Oruc

et al. 2024

Postgraduate Medicine

View full text Add to dashboard Cite

Marcadores inflamatorios como factor pronóstico en el cáncer de próstata resistente a la castración metastásico

Cited by 6 publications

References 27 publications

Prognostic efficacy of platelet/lymphocyte ratio and neutrophil/lymphocyte ratio in patients with gastric cancer

Prognostic efficacy of platelet/lymphocyte ratio and neutrophil/lymphocyte ratio in patients with gastric cancer

Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort

Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors

Contact Info

Product

Resources

About